Aptevo Therapeutics Inc.
APVO evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $3.3M
- Lead Asset:
- mipletamig (Phase 1)
What it means
What to watch
Prepared research question
What matters most for APVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APVO
Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with lead candidate mipletamig in a Phase 1b/2 trial for frontline AML and a next-generation trispecific candidate, APVO451, expected to enter IND-enabling studies in H1 2027.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.3M
Cash Runway
—
Lead Asset
mipletamig (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aptevo Therapeutics Inc..
Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with lead candidate mipletamig in a Phase 1b/2 trial for frontline AML and a next-generation trispecific candidate, APVO451, expected to enter IND-enabling studies in H1 2027.
- Aptevo is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer treatment [sec · filed 2026-08-21].
- Lead clinical candidate mipletamig (CD123xCD3 T cell engager) is being evaluated in the RAINIER Phase 1b/2 trial for frontline AML in combination with venetoclax + azacitidine [sec_mda · as of 2026-08-14].
- Cash & equivalents were $9.8M as of 2026-06-30, with net income of -$6.4M and shareholders' equity of $6.0M [sec].
- Aptevo expects to enter IND-enabling studies for its lead trispecific candidate APVO451 in H1 2027 [news · published 2026-09-24].
- The company has a 50/50 collaboration with Niowave to develop radiopharmaceutical oncology programs [news · published 2026-08-24].
What works
- Aptevo's proprietary ADAPTIR and ADAPTIR-FLEX platforms enable rational design of precision immune modulatory drugs, supporting a pipeline of two clinical and six preclinical candidates [sec_mda · as of 2026-08-14].
- Mipletamig's Phase 1 studies showed positive safety (no liver toxicity) and tolerability, with 58% of patients achieving a best response of stable disease [sec · filed 2026-08-21].
- The company secured a $1.5 million non-dilutive grant to advance APVO451 and established a 50/50 collaboration with Niowave for radiopharmaceutical programs, indicating external validation and non-dilutive funding [news · published 2026-08-24].
What to weigh
- Cash & equivalents of $9.8M as of 2026-06-30 may be insufficient to fund operations for at least one year, as the company itself notes existing cash resources are not expected to be sufficient [sec_mda · as of 2026-08-14].
- Net income of -$6.4M as of 2026-06-30 reflects ongoing operating losses typical of a clinical-stage biotech with no approved products [sec].
- The company faces numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, including potential delays in partnering and macroeconomic impacts [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Aptevo is a clinical-stage biotechnology company developing novel immunotherapy candidates for cancer.
“We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer.”
SEC filings · August 21, 2026
Mipletamig is being evaluated in the RAINIER Phase 1b/2 trial for frontline AML.
“Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trial, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine.”
SEC filings · August 14, 2026
Aptevo expects to enter IND-enabling studies for APVO451 in H1 2027.
“Aptevo expects to enter Investigational New Drug ("IND") enabling studies for the lead candidate, APVO451, in 1H2027.”
News · September 24, 2026
Cash resources are not expected to be sufficient to fund operations for at least one year.
“our existing cash resources are not expected to be sufficient to fund operations for at least one year from the date the financial statements are issued.”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- Cash runway uncertainty — Cash of $9.8M as of 2026-06-30 may not sustain operations for one year; company itself states insufficiency [sec_mda · as of 2026-08-14].
- No approved products — Net loss of -$6.4M as of 2026-06-30 reflects no revenue from product sales; all candidates are in clinical or preclinical stages [sec].
- Clinical development risks — Numerous risks and uncertainties in R&D and commercialization; potential delays in partnering and macroeconomic impacts [sec_mda · as of 2026-08-14].
What to watch
- Progress of mipletamig in the RAINIER Phase 1b/2 trial for frontline AML [sec_mda · as of 2026-08-14].
- Initiation of IND-enabling studies for APVO451 in H1 2027 [news · published 2026-09-24].
- Cash burn rate and any additional financing or partnership announcements given the limited cash runway [sec_mda · as of 2026-08-14].
- Outcomes from the Niowave radiopharmaceutical collaboration [news · published 2026-08-24].
Sources: News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Aptevo Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aptevo Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.40 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 7.8%
- Days to cover
- 2.8
- Shares short
- 92,205
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aptevo Therapeutics Inc.?
Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with lead candidate mipletamig in a Phase 1b/2 trial for frontline AML and a next-generation trispecific candidate, APVO451, expected to enter IND-enabling studies in H1 2027.
What is Aptevo Therapeutics Inc.'s lead drug candidate?
Aptevo Therapeutics Inc.'s most advanced tracked candidate is mipletamig (Phase 1) for frontline acute myelogenous leukemia (AML).
Who is the CEO of Aptevo Therapeutics Inc.?
Mr. Jeffrey G. Lamothe CA is the chief executive officer of Aptevo Therapeutics Inc. (APVO).
Where is Aptevo Therapeutics Inc. headquartered?
Aptevo Therapeutics Inc. (APVO) is headquartered in Seattle, WA, United States.
What therapeutic areas does Aptevo Therapeutics Inc. focus on?
Aptevo Therapeutics Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.